Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

udy enrolled prior to the fourth quarter of 2013.
  • Phase III study of ibrutinib versus chlorambucil in frontline newly diagnosed elderly CLL/SLL patients, RESONATE™ -2.  This trial is a randomized, multicenter, open-label study of ibrutinib as a monotherapy versus chlorambucil in patients 65 years or older with treatment naïve CLL/SLL. The study design was granted a Special Protocol Assessment (SPA), designed to demonstrate superiority of ibrutinib with the primary endpoint of progression-free survival when compared to chlorambucil. This global study is open and Pharmacyclics plans to enroll 272 patients worldwide. The Company anticipates enrollment for this study will take approximately 18 months to complete. 
  • Phase III study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory CLL/SLL, HELIOS (CLL3001). This trial is a randomized, multi-center, double blinded, placebo controlled trial of ibrutinib in combination with bendamustine and rituximab in relapsed or refractory CLL/SLL patients who received at least one line of prior systemic therapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to bendamustine and rituximab. This global study, conducted by Janssen, is open and Janssen plans to enroll 580 patients worldwide.
  • Phase II study, RESONATE™ -17p, which is a single-arm, open-label, multi-center trial using ibrutinib as a monotherapy in patients who have deletion 17p and who did not respond to or relapsed after at least one prior treatment with chemo immunotherapy (a high unmet need population). The primary endpoint of the study will be overall response rate. This global study is open and Pharmacyclics plans to enroll 111 patients worldwide. The Company anticipates enrollment for this study will take approximately 12 months to complete.
  • Phase III study of ibrutinib ver
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/22/2014)... University of Manchester have generated a new star-shaped molecule made ... its kind ever created. , Known as a ... one for over a quarter of a century and the ... . , Consisting of two molecular triangles, entwined about ... molecules are tiny each triangle is 114 atoms in ...
    (Date:9/22/2014)... , Sept. 22, 2014 US demand to ... for specialty biocides is forecast to rise 3.9 percent ... terms, demand is projected to increase 1.3 percent per ... A strong rebound in construction expenditures will support demand ... coatings markets, while growth in consumer spending and manufacturing ...
    (Date:9/22/2014)... (PRWEB) September 22, 2014 Invisible ... diagnostics for the food and beverage industries, announced ... be distributed under a non-exclusive agreement by Enartis, ... services. , Enartis, an Esseco Group company headquartered ... winemakers in California and other global markets for ...
    (Date:9/22/2014)... September 22, 2014 The US ... mixed note as the Dow Jones Industrial Average finished ... at 4,579.79, down 0.30%. The S&P 500 finished the ... six out of ten sectors finished on a positive ... the day at 751.48, up 0.10%, with the index ...
    Breaking Biology Technology:US Biocides Market 2US Biocides Market 3Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5
    ... ST. LOUIS, Oct. 2 /PRNewswire-FirstCall/ -- ... ) has elected Dr. George M. Church as a Director ... Professor of Genetics at the Harvard Medical School and Director ... Dr. Church pioneered technology innovations early in the development of ...
    ... Host Conference Call-- , CALGARY, Oct. 2 /PRNewswire-FirstCall/ - ... it has reached an agreement with the U.S. Food ... (SPA) process for the design of a Phase 3 ... in patients with platinum-refractory head and neck cancers. The ...
    ... ... the recipients of the 2009 Orange County Emerging Growth Awards, recognizing companies headquartered in ... significant growth over the last 12 months and that have made a positive impact ... ...
    Cached Biology Technology:Sigma-Aldrich Elects George M. Church as Director 2Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 5Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards 2Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards 3Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards 4
    (Date:9/22/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD ), a ... market, issues the following corporate shareholder update following the ... Letter from the CEO : ... joined the NASDAQ to support ramping of production of ... authentication products and services. This strategic achievement positions NXT-ID to ...
    (Date:9/21/2014)... (black-eyed peas) is a fascinating example of how science ... the story of the scientist behind the research. ... the 21st Century to serve as an accessible summary ... recently published by the Crop Science Society of America, ... , Singh has devoted his life,s work to solving ...
    (Date:9/21/2014)... immune T cells may have the ability to trigger ... study led by King,s College London. Although their immune ... may still be able to mount a strong immune ... Nature Medicine . , Our immune system is made ... neutrophils which play an important role in the frontline ...
    Breaking Biology News(10 mins):NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4Immune system of newborn babies is stronger than previously thought 2
    ... release is available in German . ... travel of tomorrow is meant to become quieter, cleaner and ... to accomplish just that as part of the EU ... technical aspects of air travel to the test, evaluating and ...
    ... study has highlighted the sensitivity of Australia,s species and ... ways of thinking about biodiversity conservation. ,Climate change ... natural landscapes by 2030, lead researcher, CSIRO,s Dr Michael ... be very significant and widespread. Many of the environments ...
    ... a leading software company in the clinical ... Next Generation Biobanking software platform for biomarker-based ... and academic research centers involved in biomarker-based ... effectively conduct externalized, science-driven collaborative studies. ...
    Cached Biology News:Fraunhofer supports continuation of 'Clean Sky' program 2Major changes needed to protect Australia's species and ecosystems 2BioFortis Inc., Introduces Next Generation Biobanking Software Platform for Biomarker-Based Clinical Research 2
    Takara's Mutan-Super Express Km Kit is designed to achieve site-directed mutagenesis in just one day. It is based on Oligonucleotide-directed Dual Amber (ODA) method, using the advantages of LA (Long...
    ... 4 deuterium atoms at the 9, 10, 12, ... as an internal standard for the quantification of ... produced by incubation of linoleic acid with plant ... inhibit the adhesion of tumor cells to the ...
    ... and TriEx Insect Cell Medium are recommended ... This cell/medium combination has been selected based ... protein expression levels observed specifically with baculoviruses ... that our Ready-Plaque Sf9 Cells and BacVector ...
    ...
    Biology Products: